Exploring Hepatotoxicity and Treatment Outcomes of Targeting KRAS G12C Mutations in mNSCLC - Episode 8

KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

December 21, 2023

Joshua K. Sabari, MD, Edward B. Garon, MD, MS

Experts discuss the difference in toxicities demonstrated in both adagrasib and sotorasib in second line KRAS-mutated NSCLC, highlighting hepatotoxicity and achieving durable response with combination PD-1/PD-L1 inhibitors.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: The State of Targeted Therapies in NSCLC

EP. 2: Frontline Treatments for KRAS G12C-Mutation mNSCLC

EP. 3: Clinical Perspectives of KRAS G12C Inhibitors in NSCLC Mutations

EP. 4: The Role of KRAS G12C Inhibitors in Frontline Metastatic NSCLC

EP. 5: Clinical Data Review of Hepatotoxicity in Frontline KRAS G12C Inhibition

EP. 6: Disease Progression Beyond Frontline KRAS G12C Inhibitors

EP. 7: CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

Now Viewing

EP. 8: KRAS Inhibitors: Hepatotoxicity and Adverse Events in 2L Metastatic NSCLC

EP. 9: Practical Management of Hepatotoxicity in KRAS G12C Inhibitors

EP. 10: Future Perspectives in KRAS G12C-Mutated NSCLC